This indicates that co-administration of anti-properdin MoAbs and eculizumab to PNH patients with suboptimal responses to eculizumab may be practical in a switch treatment approach, as researchers have suggested for an anti-Factor D inhibitor (93). Here, CFP is linked to paroxysmal nocturnal hemoglobinuria.